Regado Biosciences has pulled together a $40 million Series D round to push the development of a new technology designed to give doctors better control over blood clots. Edmond de Rothschild Investment Partners took the lead in the round, which was also backed by Domain Associates, Quaker Bioventures, Aurora Funds, Caxton Advantage Life Sciences Fund and other individual investors.
Basking Ridge, NJ-based Regado will use the money to pursue a new therapeutic approach to blood clots originally licensed from Duke University. Using a paired aptamer-control agent technology, its researchers believe REG1 can give physicians a tool to manage coagulation, ‘dialing' the anticoagulation effect up or down as doctors try to fight harmful clots while encouraging healing clots. The biotech released positive results from a Phase IIa clinical trial of REG1 at the European Society of Cardiology Congress at the end of August.
"Regado has a comprehensive antithrombotic pipeline, which reflects the company's expertise in the discovery and development of therapeutic aptamers with active control agents for application in the areas of both arterial and venous thrombosis," said CEO David Mazzo.
- here's Regado's release